ARGX (argenx SE) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is argenx SE LT-Debt-to-Total-Asset?

argenx SE ARGX +3.37% 78 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates ARGX with a GF Score™ of 78/100 and a GF Value™ of $1,433.22 (Significantly Undervalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. argenx SE's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

argenx SE's long-term debt to total assets ratio stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00).

argenx SE (NAS:ARGX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

argenx SE LT-Debt-to-Total-Asset Related Terms

argenx SE LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for argenx SE's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE LT-Debt-to-Total-Asset Chart

argenx SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.01

0.00

argenx SE Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.01	0.00	0.00	0.00

78GF Score

argenx SE ARGX

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

argenx SE LT-Debt-to-Total-Asset Calculation

argenx SE's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	36.327	/	8682.698
	=	0.00

argenx SE's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0	/	0
	=

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

argenx SE (ARGX) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on argenx SE and its competitors.

Is argenx SE's LT-Debt-to-Total-Asset too high?

argenx SE's current LT-Debt-to-Total-Asset is 0.00. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does argenx SE's LT-Debt-to-Total-Asset compare to VRTX and REGN?

argenx SE's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on argenx SE and its competitors. argenx SE's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is argenx SE stock overvalued right now?

Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,433.22, compared to a current price of $939.00 — trading 34.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For argenx SE (ARGX), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (ARGX) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of $939.00 is trading 34.5% below its estimated GF Value™ of $1,433.22. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for ARGX:

LT-Debt-to-Total-Asset: 0.00
GF Value™: $1,433.22 vs. price of $939.00 (34.5% below fair value)
GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Industry Healthcare Biotechnology

Comparable Companies XBRU:UCB XBRU:TUB XBRU:ONWD XBRU:HYL XBRU:ALEMS XBRU:CYAD XBRU:OXUR VRTX REGN XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA XKRX:068270 RPRX ROIV BNTX INCY

Other Exchanges ARGNF:USA ARGXb:UK 0QW0:UK 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

78GF Score

Get the complete analysis for ARGX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$939.00

Price

$1,433.22

GF Value

View ARGX Analysis

See LT-Debt-to-Total-Asset data for all stocks →